Role of N-Acetylcysteine in Acute Liver Failure

Introduction to N-Acetylcysteine Use

The American Association for the Study of Liver Diseases recommends N-acetylcysteine (NAC) should be administered promptly in all cases of acute liver failure, regardless of etiology, with strongest evidence supporting its use in acetaminophen-induced cases and emerging evidence demonstrating benefit in non-acetaminophen acute liver failure 1

NAC should be initiated immediately without waiting for confirmatory acetaminophen levels when acetaminophen overdose is known or suspected, according to the Hepatology society 2, 1
Begin treatment as early as possible, ideally within 8-10 hours of ingestion, though NAC retains benefit even when started 48 hours or more after ingestion, as suggested by the Hepatology guidelines 2
The standard acetaminophen toxicity nomogram aids in determining likelihood of serious liver damage, but cannot exclude toxicity from repeated supratherapeutic ingestions or in patients with altered metabolism, such as alcoholics or fasting patients, as noted by the Hepatology society 2

The intravenous route is preferred, with a loading dose of 150 mg/kg in 5% dextrose over 15 minutes, followed by 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours, as recommended by the Hepatology guidelines 2, 3
The oral route may be used, with a 140 mg/kg loading dose, followed by 70 mg/kg every 4 hours for 17 doses, according to the Hepatology society 2, 3

NAC reduces progression to grade III-IV encephalopathy and mortality, with a significant improvement in 21-day survival, as demonstrated by a placebo-controlled trial 1
Meta-analysis shows NAC significantly reduces hepatotoxicity and mortality, with a relative risk of 0.31 and 0.12, respectively, as reported by the Anaesthesia journal 1

NAC should be initiated in all cases of acute liver failure regardless of etiology to improve transplant-free survival and post-transplant outcomes, according to the Anaesthesia guidelines 1
This represents a GRADE 2+ recommendation with strong agreement from intensive care guidelines, reflecting lower quality evidence than acetaminophen cases but meaningful clinical benefit, as noted by the Anaesthesia journal 1

Transplant-free survival improves significantly with NAC, with an odds ratio of 1.61, as demonstrated by a meta-analysis 1, 3
Overall survival benefit in adults is significant, with an odds ratio of 2.30, as reported by the Anaesthesia journal 1, 3
Post-transplant survival is also improved, with an odds ratio of 2.44, as noted by the Anaesthesia journal 1

Administer NAC in any case of acute liver failure where acetaminophen ingestion is possible or when circumstances surrounding admission are inadequate, as recommended by the Hepatology society 2
Given NAC's safety profile and potential benefit, treatment should not be delayed while awaiting diagnostic confirmation, according to the Anaesthesia guidelines 1, 3

Adverse effects are minimal, with nausea, vomiting, diarrhea, or constipation, as reported by the Anaesthesia journal 1
Skin rash occurs in less than 5% of patients, and transient bronchospasm occurs in 1-2% of cases, as noted by the Anaesthesia journal and the Praxis Medical Insights guidelines 1, 3

Contact with a liver transplant center should be initiated early in the evaluation process for all patients with acute liver failure, as recommended by the Hepatology society 2
Patients with acute liver failure should be admitted to an intensive care unit with frequent monitoring, including liver function tests and coagulation parameters, as suggested by the Hepatology and Praxis Medical Insights guidelines 2, 3